Results 81 to 90 of about 128,993 (222)
Combining HDX‐MS and NMR enables the mapping of epitopes and paratopes in full‐length antibody complexes, revealing transient interactions and potential artifacts. ABSTRACT Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation,
Francesca Sacco +13 more
wiley +2 more sources
Evaluation of Methods Employed in Establishing Preclinical Similarity of Adalimumab Biosimilars
Adalimumab, marketed as Humira, is a fully humanized monoclonal antibody that blocks the activity of tumor necrosis factor-alpha and is used in treating several autoimmune disorders. As one of the top-grossing pharmaceuticals, its global sales surpassed $
Ramya Nair +3 more
doaj +1 more source
Real‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort
ABSTRACT Rituximab is endorsed internationally as first‐line therapy for moderate‐to‐severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single‐centre retrospective cohort, 24 adults with pemphigus vulgaris (n = 16) or pemphigus foliaceus (n = 8) received rituximab as part of routine ...
Pokphazz Christjaroon +4 more
wiley +1 more source
Background Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been reported up ...
Xiaomei Leng +15 more
doaj +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Biosimilar Drugs for Therapy of Immune-Mediated Diseases
In recent years, biological therapy has been widely used for the treatment of immunemediated diseases in rheumatology, hematology, gastroenterology, etc.
Tsvetelina Velikova
core +1 more source
Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis +4 more
wiley +1 more source
Background Biosimilar etanercept presents itself as an innovative therapeutic opportunity for inflammatory and autoimmune diseases, however, its efficacy, safety, and immunogenicity in relation to the reference biological agent for the treatment of ...
Aurélio Matos Andrade +4 more
doaj +1 more source
Background The ZOHé study was a prospective, non-interventional, multicentre study in France to assess the use of biosimilar filgrastim Zarzio® (Sandoz filgrastim) in routine clinical practice in patients at risk of neutropenia-inducing chemotherapy (CT).
Henri Roché +8 more
doaj +1 more source
Acknowledgement to Reviewers of Pharmaceuticals in 2014
The editors of Pharmaceuticals would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2014:[...
Pharmaceuticals Editorial Office
core +1 more source

